1.
SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity. O’Connell P, Blake MK, Godbehere S, Amalfitano A, Aldhamen YA.
J Neuroinflammation. 2022 Oct 3;19(1):241. doi: 10.1186/s12974-022-02594-9.
PMID: 36199066
2.
Postnatal deletion of Spns2 prevents neuroinflammation without compromising blood vascular functions. Hasan Z, Nguyen TQ, Lam BWS, Wong JHX, Wong CCY, Tan CKH, Yu J, Thiam CH, Zhang Y, Angeli V, Nguyen LN.
Cell Mol Life Sci. 2022 Oct 5;79(11):541. doi: 10.1007/s00018-022-04573-y.
PMID: 36198832
3.
[Progressive Multifocal Leukoencephalopathy: An Overview of Current Topics]. Yukitake M.
Brain Nerve. 2022 Oct;74(10):1179-1187. doi: 10.11477/mf.1416202206.
PMID: 36198643 Japanese.
4.
Association of autoimmune diseases with Alzheimer’s disease: A mendelian randomization study. Yeung CHC, Au Yeung SL, Schooling CM.
J Psychiatr Res. 2022 Sep 29;155:550-558. doi: 10.1016/j.jpsychires.2022.09.052. Online ahead of print.
PMID: 36198219
5.
Electronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational Study. Sieber C, Chiavi D, Haag C, Kaufmann M, Horn AB, Dressel H, Zecca C, Calabrese P, Pot C, Kamm CP, von Wyl V; Swiss Multiple Sclerosis Registry.
JMIR Mhealth Uhealth. 2022 Oct 5;10(10):e38709. doi: 10.2196/38709.
PMID: 36197713
6.
First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center. Skarlis C, Markoglou N, Gontika M, Bougea A, Katsavos S, Artemiadis A, Chrousos G, Dalakas M, Stefanis L, Anagnostouli M.
Neurol Sci. 2022 Oct 5. doi: 10.1007/s10072-022-06431-y. Online ahead of print.
PMID: 36197577
7.
Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP. Brugarolas P, Wilks MQ, Noel J, Kaiser JA, Vesper DR, Ramos-Torres KM, Guehl NJ, Macdonald-Soccorso MT, Sun Y, Rice PA, Yokell DL, Lim R, Normandin MD, El Fakhri G.
Eur J Nucl Med Mol Imaging. 2022 Oct 5. doi: 10.1007/s00259-022-05980-w. Online ahead of print.
PMID: 36197499
8.
[Radicalization and “forced emigration”: the dismissal and expulsion of neuroscientists and neuropsychiatrists from Vienna]. Martin M, Fangerau H, Karenberg A.
Nervenarzt. 2022 Oct;93(Suppl 1):80-91. doi: 10.1007/s00115-022-01326-x. Epub 2022 Oct 5.
PMID: 36197479 Review. German.
9.
Pulmonary lymphangioleiomyomatosis and renal angiomyolipoma in a patient with systemic lupus erythematosus: A case report. Koh JS, Oh S, Chung C.
Medicine (Baltimore). 2022 Sep 23;101(38):e30554. doi: 10.1097/MD.0000000000030554.
PMID: 36197220
10.
Random Skin Biopsy Is a Useful Procedure in the Evaluation of Hemophagocytic Lymphohistiocytosis: A Case Report and Review of Literature. Hegazy S, Moesch J, Guerrero A, Ho J, Karunamurthy A.
Am J Dermatopathol. 2022 Sep 27. doi: 10.1097/DAD.0000000000002301. Online ahead of print.
PMID: 36197063
1.
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases. Fernández-Calle R, Konings SC, Frontiñán-Rubio J, García-Revilla J, Camprubí-Ferrer L, Svensson M, Martinson I, Boza-Serrano A, Venero JL, Nielsen HM, Gouras GK, Deierborg T.
Mol Neurodegener. 2022 Sep 24;17(1):62. doi: 10.1186/s13024-022-00566-4.
PMID: 36153580 Review.
2.
In vivo quantification of brain soma and neurite density abnormalities in multiple sclerosis. Margoni M, Pagani E, Preziosa P, Palombo M, Gueye M, Azzimonti M, Filippi M, Rocca MA.
J Neurol. 2022 Sep 24. doi: 10.1007/s00415-022-11386-3. Online ahead of print.
PMID: 36153468
3.
Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. Jand Y, Ghahremani MH, Ghanbari A, Ejtemaei-Mehr S, Guillemin GJ, Ghazi-Khansari M.
Sci Rep. 2022 Sep 24;12(1):15963. doi: 10.1038/s41598-022-20164-0.
PMID: 36153399
4.
Gut microbiome in multiple sclerosis-related cognitive impairment. Ghadiri F, Ebadi Z, Asadollahzadeh E, Naser Moghadasi A.
Mult Scler Relat Disord. 2022 Sep 7;67:104165. doi: 10.1016/j.msard.2022.104165. Online ahead of print.
PMID: 36152393 Review.
5.
Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study. Araujo L, Geertsen SS, Amedume A, Higuchi K, van Wingerden J.
Neurol Ther. 2022 Sep 24. doi: 10.1007/s40120-022-00404-1. Online ahead of print.
PMID: 36152222
6.
Isobaric Incorporation of C13-Histidine for the Assessment of Remyelination. Harvey FC, Valdivia AO, Hayter C, Bhattacharya SK.
Methods Mol Biol. 2023;2571:169-175. doi: 10.1007/978-1-0716-2699-3_17.
PMID: 36152161
7.
Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis. Pagani E, Storelli L, Pantano P, Petsas N, Tedeschi G, Gallo A, De Stefano N, Battaglini M, Rocca MA, Filippi M; INNI Network.
J Neurol. 2022 Sep 24. doi: 10.1007/s00415-022-11387-2. Online ahead of print.
PMID: 36152049
8.
Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors. Boumaza X, Bonneau B, Roos-Weil D, Pinnetti C, Rauer S, Nitsch L, Del Bello A, Jelcic I, Sühs KW, Gasnault J, Goreci Y, Grauer O, Gnanapavan S, Wicklein R, Lambert N, Perpoint T, Beudel M, Clifford D, Sommet A, Cortese I, Martin-Blondel G; Immunotherapy for PML study group.
Ann Neurol. 2022 Sep 24. doi: 10.1002/ana.26512. Online ahead of print.
PMID: 36151879
9.
Staufen impairs autophagy in neurodegeneration. Paul S, Dansithong W, Gandelman M, Figueroa KP, Zu T, Ranum LPW, Scoles DR, Pulst SM.
Ann Neurol. 2022 Sep 23. doi: 10.1002/ana.26515. Online ahead of print.
PMID: 36151701
1.
Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials. Snetselaar L, Cheek JJ, Fox SS, Healy HS, Schweizer ML, Bao W, Kamholz J, Titcomb TJ.
Neurology. 2022 Oct 18:10.1212/WNL.0000000000201371. doi: 10.1212/WNL.0000000000201371. Online ahead of print.
PMID: 36257717
2.
The Role of Diet in Multiple Sclerosis: Food for Thought. Spain R, Piccio L, Langer-Gould AM.
Neurology. 2022 Oct 18:10.1212/WNL.0000000000201565. doi: 10.1212/WNL.0000000000201565. Online ahead of print.
PMID: 36257715 No abstract available.
3.
Gut microbiota manipulation as an epilepsy treatment. Iannone LF, Eguilaz MG, De Caro C.
Neurobiol Dis. 2022 Oct 15:105897. doi: 10.1016/j.nbd.2022.105897. Online ahead of print.
PMID: 36257595
4.
SYK coordinates neuroprotective microglial responses in neurodegenerative disease. Ennerfelt H, Frost EL, Shapiro DA, Holliday C, Zengeler KE, Voithofer G, Bolte AC, Lammert CR, Kulas JA, Ulland TK, Lukens JR.
Cell. 2022 Oct 6:S0092-8674(22)01249-1. doi: 10.1016/j.cell.2022.09.030. Online ahead of print.
PMID: 36257314
5.
Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis. Talbot J, Højsgaard Chow H, Mahler M, Buhelt S, Holm Hansen R, Lundell H, Vinther-Jensen T, Hellem MNN, Nielsen JE, Siebner HR, von Essen MR, Sellebjerg F.
Mult Scler Relat Disord. 2022 Oct 3;68:104209. doi: 10.1016/j.msard.2022.104209. Online ahead of print.
PMID: 36257152
6.
Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis. Zjukovskaja C, Larsson A, Cherif H, Kultima K, Burman J.
Mult Scler Relat Disord. 2022 Oct 3;68:104210. doi: 10.1016/j.msard.2022.104210. Online ahead of print.
PMID: 36257151
7.
Participant characteristics of existing exercise studies in persons with multiple sclerosis – A systematic review identifying literature gaps. Gaemelke T, Frandsen JJ, Hvid LG, Dalgas U.
Mult Scler Relat Disord. 2022 Oct 3;68:104198. doi: 10.1016/j.msard.2022.104198. Online ahead of print.
PMID: 36257149 Review.
8.
THE ROLE OF DIET IN MULTIPLE SCLEROSIS. Carbogno-Barnabe V, Łabuz-Roszak B.
Wiad Lek. 2022;75(9 pt 1):2131-2135. doi: 10.36740/WLek202209115.
PMID: 36256941
9.
Treatment with an antigen-specific dual microparticle system reverses advanced multiple sclerosis in mice. Kwiatkowski AJ, Helm EY, Stewart JM, Drashansky TT, Cho JJ, Avram D, Keselowsky BG.
Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2205417119. doi: 10.1073/pnas.2205417119. Epub 2022 Oct 18.
PMID: 36256820
10.
Telemedicine for neurologic diseases: A systematic review and meta-analysis. León-Salas B, González Hernández Y, Infante-Ventura D, de Armas Castellano A, García García J, García Hernández M, Carmona Rodríguez M, Olazarán J, Dobato JL, Rodríguez-Rodríguez L, Trujillo-Martín MM.
Eur J Neurol. 2022 Oct 18. doi: 10.1111/ene.15599. Online ahead of print.
PMID: 36256522 Review.
11.
Prediction of the information processing speed performance in multiple sclerosis using a machine learning approach in a large multicenter magnetic resonance imaging data set. Marzi C, d’Ambrosio A, Diciotti S, Bisecco A, Altieri M, Filippi M, Rocca MA, Storelli L, Pantano P, Tommasin S, Cortese R, De Stefano N, Tedeschi G, Gallo A, The Inni Network.
Hum Brain Mapp. 2022 Oct 18. doi: 10.1002/hbm.26106. Online ahead of print.
PMID: 36255155
12.
The effects and potential of microglial polarization and crosstalk with other cells of the central nervous system in the treatment of Alzheimer’s disease. Wu YG, Song LJ, Yin LJ, Yin JJ, Wang Q, Yu JZ, Xiao BG, Ma CG.
Neural Regen Res. 2023 May;18(5):947-954. doi: 10.4103/1673-5374.355747.
PMID: 36254973 Review.
13.
Flow volume measurement of arterial venous and cerebrospinal fluid in patients with multiple sclerosis. Aglamis S, Gönen M.
Arq Neuropsiquiatr. 2022 Jul;80(7):706-711. doi: 10.1055/s-0042-1755276. Epub 2022 Sep 29.
PMID: 36254443 English.
14.
Brain volume loss and physical and cognitive impairment in naive multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina. Rojas JI, Patrucco L, Pappolla A, Sánchez F, Cristiano E.
Arq Neuropsiquiatr. 2022 Jul;80(7):699-705. doi: 10.1055/s-0042-1755277. Epub 2022 Sep 29.
PMID: 36254442 English.
15.
Objective perimetry and progression of multiple sclerosis. Maddess T, Carle CF, Rohan EMF, Baird-Gunning J, van Kleef JP, Lueck CJ.
eNeurologicalSci. 2022 Oct 8;29:100430. doi: 10.1016/j.ensci.2022.100430. eCollection 2022 Dec.
PMID: 36254171 Free PMC article.
16.
Correlation between ERα gene polymorphism and multiple sclerosis and neuromyelitis optica. Xing W, Hong M, Wei Z, Zhang W.
Medicine (Baltimore). 2022 Oct 14;101(41):e31126. doi: 10.1097/MD.0000000000031126.
PMID: 36254093
17.
Do Impulse Control Disorders Impair Car Driving Performance in Patients with Parkinson’s Disease? Fründt O, Fadhel M, Heesen C, Seddiq Zai S, Gerloff C, Vettorazzi E, Pöttgen J, Buhmann C.
J Parkinsons Dis. 2022;12(7):2261-2275. doi: 10.3233/JPD-223420.
PMID: 36120790
1.
Beyond ocrelizumab in primary progressive multiple sclerosis. Williams T, Chataway J.
Nat Rev Neurol. 2022 Sep 22. doi: 10.1038/s41582-022-00724-8. Online ahead of print.
PMID: 36138171 No abstract available.
2.
Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, Patti F, Pozzilli C, Preziosa P, Trojano M.
J Neurol. 2022 Sep 22. doi: 10.1007/s00415-022-11385-4. Online ahead of print.
PMID: 36138162 No abstract available.
3.
Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes. Yılmaz Ü, Gücüyener K, Yavuz M, Öncel İ, Canpolat M, Saltık S, Ünver O, Çıtak Kurt AN, Tosun A, Yılmaz S, Özgör B, Erol İ, Öztoprak Ü, Elitez DA, Direk MÇ, Bodur M, Teber S, Anlar B; Turkish Pediatric Multiple Sclerosis Study Group.
Eur J Paediatr Neurol. 2022 Sep 1;41:8-18. doi: 10.1016/j.ejpn.2022.08.006. Online ahead of print.
PMID: 36137476
4.
COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis. Albanese A, Sormani MP, Gattorno G, Schiavetti I.
Mult Scler Relat Disord. 2022 Sep 5;68:104156. doi: 10.1016/j.msard.2022.104156. Online ahead of print.
PMID: 36137347 Review.
5.
Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches. Abuaf AF, Bunting SR, Klein S, Carroll T, Carpenter-Thompson J, Javed A, Cipriani V.
PLoS One. 2022 Sep 22;17(9):e0274778. doi: 10.1371/journal.pone.0274778. eCollection 2022.
PMID: 36137122
6.
SIRT1 inactivation switches reactive astrocytes to an anti-inflammatory phenotype in CNS autoimmunity. Zhang W, Xiao D, Li X, Zhang Y, Rasouli J, Casella G, Boehm A, Hwang D, Ishikawa LL, Thome R, Ciric B, Curtis MT, Rostami A, Zhang GX.
J Clin Invest. 2022 Sep 22:e151803. doi: 10.1172/JCI151803. Online ahead of print.
PMID: 36136587
7.
Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study. Baccouche I, Bensmail D, Leblong E, Fraudet B, Aymard C, Quintaine V, Pottier S, Lansaman T, Malot C, Gallien P, Levy J.
Toxins (Basel). 2022 Aug 24;14(9):582. doi: 10.3390/toxins14090582.
PMID: 36136520
8.
Dysregulated Sulfide Metabolism in Multiple Sclerosis: Serum and Vascular Endothelial Inflammatory Responses. Veerareddy P, Dao N, Yun JW, Stokes KY, Disbrow E, Kevil CG, Cvek U, Trutschl M, Kilgore P, Ramanathan M, Zivadinov R, Alexander JS.
Pathophysiology. 2022 Sep 17;29(3):570-582. doi: 10.3390/pathophysiology29030044.
PMID: 36136071
9.
Erdheim-Chester Disease with Isolated CNS Involvement: A Systematic Review of the Literature. Haque A, Pérez CA, Reddy TA, Gupta RK.
Neurol Int. 2022 Sep 5;14(3):716-726. doi: 10.3390/neurolint14030060.
PMID: 36135995 Review.
10.
A Patient with Erdheim-Chester Disease Limited to Central Nervous System. Gupta RK, Haque A, Reddy TA, Pérez CA.
Neurol Int. 2022 Aug 26;14(3):678-682. doi: 10.3390/neurolint14030056.
PMID: 36135991
11.
The borderland of Multiple sclerosis and Functional Neurological Disorder: a call for clinical research and vigilance. Aybek S, Chan A.
Eur J Neurol. 2022 Sep 22. doi: 10.1111/ene.15568. Online ahead of print.
PMID: 36135345
12.
Oral Health Status and Multiple Sclerosis: Classic and Non-Classic Manifestations-Case Report. Costa C, Santiago H, Pereira S, Castro AR, Soares SC.
Diseases. 2022 Sep 9;10(3):62. doi: 10.3390/diseases10030062.
PMID: 36135218
13.
Optic Neuritis in Multiple Sclerosis-A Review of Molecular Mechanisms Involved in the Degenerative Process. Ciapă MA, Șalaru DL, Stătescu C, Sascău RA, Bogdănici CM.
Curr Issues Mol Biol. 2022 Sep 2;44(9):3959-3979. doi: 10.3390/cimb44090272.
PMID: 36135184 Review.
14.
The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients. Asadollahzade E, Ghadiri F, Ebadi Z, Moghadasi AN.
Rev Assoc Med Bras (1992). 2022 Aug;68(8):979-981. doi: 10.1590/1806-9282.20220643.
PMID: 36134822 No abstract available.
15.
IL-10-Functionalized Hydrogels Support Immunosuppressive Dendritic Cell Phenotype and Function. Beskid NM, Kolawole EM, Coronel MM, Nguyen B, Evavold B, García AJ, Babensee JE.
ACS Biomater Sci Eng. 2022 Sep 22. doi: 10.1021/acsbiomaterials.2c00465. Online ahead of print.
PMID: 36134725
16.
Thyroid hormone-dependent oligodendroglial cell lineage genomic and non-genomic signaling through integrin receptors. Emamnejad R, Dass M, Mahlis M, Bozkurt S, Ye S, Pagnin M, Theotokis P, Grigoriadis N, Petratos S.
Front Pharmacol. 2022 Sep 5;13:934971. doi: 10.3389/fphar.2022.934971. eCollection 2022.
PMID: 36133808 Free PMC article. Review.
17.
Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries. Bentley S, Morgan L, Exall E, Arbuckle R, Rossom RC, Roche N, Khunti K, Higgins V, Piercy J.
Patient Prefer Adherence. 2022 Sep 15;16:2579-2592. doi: 10.2147/PPA.S358046. eCollection 2022.
PMID: 36133076 Free PMC article.
18.
Clinical application of transcranial magnetic stimulation in multiple sclerosis. Zhou X, Li K, Chen S, Zhou W, Li J, Huang Q, Xu T, Gao Z, Wang D, Zhao S, Dong H.
Front Immunol. 2022 Sep 5;13:902658. doi: 10.3389/fimmu.2022.902658. eCollection 2022.
PMID: 36131925 Free PMC article. Review.
19.
Early-life stress and dietary fatty acids impact the brain lipid/oxylipin profile into adulthood, basally and in response to LPS. Reemst K, Broos JY, Abbink MR, Cimetti C, Giera M, Kooij G, Korosi A.
Front Immunol. 2022 Sep 5;13:967437. doi: 10.3389/fimmu.2022.967437. eCollection 2022.
PMID: 36131915 Free PMC article.
20.
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis. Chang I, Kappos L, Giovannoni G, Calabresi PA, Sandrock A, Cheng W, Xiao S, Riester K, Belachew S, Deykin A, Zhu B.
Mult Scler. 2022 Sep 21:13524585221114997. doi: 10.1177/13524585221114997. Online ahead of print.
PMID: 36131595
21.
Impact of Adherence with Disease-Modifying Therapies on All-Cause Mortality Rates Among Veterans with Multiple Sclerosis. Rabadi MH, Just K, Xu C.
Med Sci Monit. 2022 Sep 22;28:e938116. doi: 10.12659/MSM.938116.
PMID: 36131525
22.
All anti-CD20 monoclonal antibodies have similar efficacy and risks: No. Sellebjerg F, Romme Christensen J.
Mult Scler. 2022 Oct;28(12):1845-1846. doi: 10.1177/13524585221103729.
PMID: 36124837 No abstract available.
23.
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. Calabrese C, Kirchner E, Villa-Forte A, Hajj-Ali RA, Moss BP, Fernandez JP, Calabrese L.
RMD Open. 2022 Sep;8(2):e002557. doi: 10.1136/rmdopen-2022-002557.
PMID: 36123015 Free PMC article. No abstract available.
24.
Sclérose en plaques de forme fulminante chez un homme de 36 ans. Zaeem Z, Emery D, Blevins G.
CMAJ. 2022 Sep 19;194(36):E1269-E1270. doi: 10.1503/cmaj.211807-f.
PMID: 36122920 French. No abstract available.
1.
Investigating Functional Network Abnormalities and Associations With Disability in Multiple Sclerosis. Carotenuto A, Valsasina P, Schoonheim MM, Geurts JJ, Barkhof F, Gallo A, Tedeschi G, Tommasin S, Pantano P, Filippi M, Rocca MA; MAGNIMS Study Group.
Neurology. 2022 Sep 12:10.1212/WNL.0000000000201264. doi: 10.1212/WNL.0000000000201264. Online ahead of print.
PMID: 36096690
2.
Mortality and cause of death in multiple sclerosis in western Norway 1950-2021: a registry-based linkage study. Willumsen JS, Grytten N, Aarseth J, Myklebust TÅ, Myhr KM, Midgard R.
J Neurol Neurosurg Psychiatry. 2022 Sep 12:jnnp-2022-329169. doi: 10.1136/jnnp-2022-329169. Online ahead of print.
PMID: 36096665
3.
Multiple Folliculocystic and Collagen Hamartomas in a Patient with Tuberous Sclerosis Complex. Giacaman A, Saus Sarrias C, González-López G, Martín-Santiago A.
Actas Dermosifiliogr. 2022 Sep 9:S0001-7310(22)00775-X. doi: 10.1016/j.ad.2022.09.002. Online ahead of print.
PMID: 36096233 English, Spanish. No abstract available.
4.
Breastfeeding and risk of multiple sclerosis: a systematic review and meta-analysis of observational studies. Holz A, Riefflin M, Heesen C, Riemann-Lorenz K, Obi N, Becher H.
Neuroepidemiology. 2022 Sep 12. doi: 10.1159/000526895. Online ahead of print.
PMID: 36096115
5.
Epstein-Barr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location. Olmez O, Baba C, Abasiyanik Z, Ozakbas S.
Mult Scler Relat Disord. 2022 Aug 28;68:104149. doi: 10.1016/j.msard.2022.104149. Online ahead of print.
PMID: 36096010
6.
Web-Based Mindfulness-Based Interventions for Well-being: Randomized Comparative Effectiveness Trial. Sylvia LG, Lunn MR, Obedin-Maliver J, McBurney RN, Nowell WB, Nosheny RL, Mularski RA, Long MD, Merkel PA, Pletcher MJ, Tovey RE, Scalchunes C, Sutphen R, Martin AS, Horn EJ, O’Boyle M, Pitch L, Seid M, Redline S, Greenebaum S, George N, French NJ, Faria CM, Puvanich N, Rabideau DJ, Selvaggi CA, Yu C, Faraone SV, Venkatachalam S, McCall D, Terry SF, Deckersbach T, Nierenberg AA.
J Med Internet Res. 2022 Sep 12;24(9):e35620. doi: 10.2196/35620.
PMID: 36094813
7.
Lesion-Specific Metabolic Alterations in Relapsing-Remitting Multiple Sclerosis Via 7 T Magnetic Resonance Spectroscopic Imaging. Lipka A, Niess E, Dal-Bianco A, Hangel GJ, Rommer PS, Strasser B, Motyka S, Hingerl L, Berger T, Hnilicová P, Kantorová E, Leutmezer F, Kurča E, Gruber S, Trattnig S, Bogner W.
Invest Radiol. 2022 Sep 8. doi: 10.1097/RLI.0000000000000913. Online ahead of print.
PMID: 36094811
8.
The Design, Development, and Testing of a Virtual Reality Device for Upper Limb Training in People With Multiple Sclerosis: Single-Center Feasibility Study. Kalron A, Frid L, Fonkatz I, Menascu S, Dolev M, Magalashvili D, Achiron A.
JMIR Serious Games. 2022 Sep 12;10(3):e36288. doi: 10.2196/36288.
PMID: 36094809
9.
Fampridine in multiple sclerosis patients with acute phase of cervical transverse myelitis: a double-blind, randomized placebo-controlled trial. Amini Harandi A, Pakdaman H, Karamiani F, Mohammadi F, Shirzadeh Barough S, Siavoshi F, Ilkhani S, Sahraian M.
Neurol Sci. 2022 Sep 12. doi: 10.1007/s10072-022-06380-6. Online ahead of print.
PMID: 36094772
10.
Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies. Nicolas P, Marion-Moffet H, Gossez M, Vukusic S, Monneret G, Marignier R, Venet F.
J Neurol. 2022 Sep 12. doi: 10.1007/s00415-022-11353-y. Online ahead of print.
PMID: 36094632 No abstract available.
11.
Retinal Thinning in People With Well-Controlled HIV Infection. Geannopoulos K, McMahan C, Maldonado RS, Abbott A, Knickelbein J, Agron E, Wu T, Snow J, Nair G, Horne E, Lau CY, Nath A, Chew EY, Smith BR.
J Acquir Immune Defic Syndr. 2022 Oct 1;91(2):210-216. doi: 10.1097/QAI.0000000000003048.
PMID: 36094488
12.
The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis. Topic A, Vasic M, Markovic B, Milinkovic N, Dincic E.
Clin Neuropharmacol. 2022 Sep 7. doi: 10.1097/WNF.0000000000000519. Online ahead of print.
PMID: 36093923
13.
Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis. Adamec I, Habek M.
Clin Neuropharmacol. 2022 Sep 8. doi: 10.1097/WNF.0000000000000522. Online ahead of print.
PMID: 36093911
14.
Phase 1 Evaluation of Elezanumab (anti-RGMa mAb) in Healthy and MS Participants. Kalluri HV, Rosebraugh MR, Misko TP, Ziemann A, Liu W, Cree BAC.
Ann Neurol. 2022 Sep 12. doi: 10.1002/ana.26503. Online ahead of print.
PMID: 36093738
15.
Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier? Tepavčević V, Lubetzki C.
Brain. 2022 Sep 12:awac307. doi: 10.1093/brain/awac307. Online ahead of print.
PMID: 36093726
16.
Arctigenin: pharmacology, total synthesis, and progress in structure modification. Wu D, Jin L, Huang X, Deng H, Shen QK, Quan ZS, Zhang C, Guo HY.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2452-2477. doi: 10.1080/14756366.2022.2115035.
PMID: 36093586
17.
Review: Cannabinoids as Medicinals. Khalsa JH, Bunt G, Blum K, Maggirwar SB, Galanter M, Potenza MN.
Curr Addict Rep. 2022 Sep 7:1-17. doi: 10.1007/s40429-022-00438-3. Online ahead of print.
PMID: 36093358 Free PMC article. Review.
18.
Expression of T cell-related lncRNAs in multiple sclerosis. Dadyar M, Hussen BM, Eslami S, Taheri M, Emadi F, Ghafouri-Fard S, Sayad A.
Front Genet. 2022 Aug 26;13:967157. doi: 10.3389/fgene.2022.967157. eCollection 2022.
PMID: 36092928 Free PMC article.
19.
Epigenetic clock indicates accelerated aging in glial cells of progressive multiple sclerosis patients. Kular L, Klose D, Urdánoz-Casado A, Ewing E, Planell N, Gomez-Cabrero D, Needhamsen M, Jagodic M.
Front Aging Neurosci. 2022 Aug 24;14:926468. doi: 10.3389/fnagi.2022.926468. eCollection 2022.
PMID: 36092807 Free PMC article.
20.
Fingolimod versus interferon beta 1-a: Benefit-harm assessment approach based on TRANSFORMS individual patient data. Spanu A, Aschmann HE, Kesselring J, Puhan MA.
Mult Scler J Exp Transl Clin. 2022 Sep 7;8(3):20552173221117784. doi: 10.1177/20552173221117784. eCollection 2022 Jul-Sep.
PMID: 36092642 Free PMC article.
21.
Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis. Alanazi A, Alassiri M, Jawdat D, Almalik Y.
Regen Ther. 2022 Aug 23;21:201-209. doi: 10.1016/j.reth.2022.07.003. eCollection 2022 Dec.
PMID: 36092509 Free PMC article. Review.
22.
‘That would have been the perfect thing after diagnosis’: development of a digital lifestyle management application in multiple sclerosis. Krause N, Riemann-Lorenz K, Rahn AC, Pöttgen J, Köpke S, Meyer B, Thale F, Temmes H, van de Loo M, Gold SM, Heesen C.
Ther Adv Neurol Disord. 2022 Sep 6;15:17562864221118729. doi: 10.1177/17562864221118729. eCollection 2022.
PMID: 36092248 Free PMC article.
23.
Bu Shen Yi Sui Capsule Promotes Myelin Repair by Modulating the Transformation of A1/A2 Reactive Astrocytes In Vivo and In Vitro. Zha Z, Liu YJ, Liu SS, Zhang N, Li JL, Qi F, Jin LY, Xue B, Yang T, Fan YP, Zhao H, Wang L.
Oxid Med Cell Longev. 2022 Sep 1;2022:3800004. doi: 10.1155/2022/3800004. eCollection 2022.
PMID: 36092158 Free PMC article.
24.
A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP. Barello S, Paolicelli D, Bergamaschi R, Cottone S, D’Amico A, Annibali V, Paolillo A, Bosio C, Panetta V, Graffigna G.
Front Psychol. 2022 Aug 24;13:965229. doi: 10.3389/fpsyg.2022.965229. eCollection 2022.
PMID: 36092091 Free PMC article.
25.
Effects of age, sex, and education on California Verbal Learning Test-II performance in a Chinese-speaking population. Lou F, Yang G, Cai L, Yu L, Zhang Y, Shi C, Zhang N.
Front Psychol. 2022 Aug 25;13:935875. doi: 10.3389/fpsyg.2022.935875. eCollection 2022.
PMID: 36092060 Free PMC article.
26.
Clinicopathological manifestations of coexistent monoclonal immunoglobulin deposition disease and immunotactoid glomerulopathy. Wang Y, Yan Y, Dong B, Zou W, Li X, Shao C, Jiang L, Wang M, Zuo L.
Front Med (Lausanne). 2022 Aug 25;9:911998. doi: 10.3389/fmed.2022.911998. eCollection 2022.
PMID: 36091681 Free PMC article.
27.
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study. Frahm N, Fneish F, Ellenberger D, Haas J, Loebermann M, Parciak T, Peters M, Pöhlau D, Rodgers J, Röper AL, Schilling S, Stahmann A, Temmes H, Zettl UK, Middleton RM.
Lancet Reg Health Eur. 2022 Sep 2;22:100502. doi: 10.1016/j.lanepe.2022.100502. eCollection 2022 Nov.
PMID: 36090519 Free PMC article.
28.
Presentations and Treatment of Multiple Sclerosis in Pakistan: A Retrospective Review of 188 Cases. Shah Z, Khan M, Rajput HM, Wasay M.
Int J MS Care. 2022 Sep-Oct;24(5):vi. doi: 10.7224/1537-2073.2022-008. Epub 2022 Aug 15.
PMID: 36090244 Free PMC article. No abstract available.
29.
Predictors of Mood Disorders in Parents With Multiple Sclerosis: The Role of Disability Level, Coping Techniques, and Perceived Social Support. Podda J, Uccelli MM, Tacchino A, Pedullà L, Bragadin MM, Battaglia MA, Brichetto G, Ponzio M.
Int J MS Care. 2022 Sep-Oct;24(5):224-229. doi: 10.7224/1537-2073.2021-101. Epub 2022 Jun 20.
PMID: 36090243 Free PMC article.
30.
Neurogenic Bowel Dysfunction Over the Course of Multiple Sclerosis: A Review. Gulick EE.
Int J MS Care. 2022 Sep-Oct;24(5):209-217. doi: 10.7224/1537-2073.2021-007. Epub 2022 Jun 20.
PMID: 36090242 Free PMC article.
31.
Effects of Nonconsecutive Sessions of Transcranial Direct Current Stimulation and Stationary Cycling on Walking Capacity in Individuals With Multiple Sclerosis. Rahimibarghani S, Azadvari M, Emami-Razavi SZ, Harirchian MH, Rahimi-Dehgolan S, Fateh HR.
Int J MS Care. 2022 Sep-Oct;24(5):202-208. doi: 10.7224/1537-2073.2021-004. Epub 2022 Jun 22.
PMID: 36090241 Free PMC article.
32.
Facilitators of and Barriers to Adherence to Dietary Interventions Perceived by Women With Multiple Sclerosis and Their Support Persons. Dean C, Parks S, Titcomb TJ, Arthofer A, Meirick P, Grogan N, Ehlinger MA, Bisht B, Fox SS, Daack-Hirsch S, Snetselaar LG, Wahls TL.
Int J MS Care. 2022 Sep-Oct;24(5):235-241. doi: 10.7224/1537-2073.2021-051. Epub 2022 May 26.
PMID: 36090239 Free PMC article.
33.
Characterizing Relationships Between Cognitive, Mental, and Physical Health and Physical Activity Levels in Persons With Multiple Sclerosis. Tyszka EE, Bozinov N, Briggs FBS.
Int J MS Care. 2022 Sep-Oct;24(5):242-249. doi: 10.7224/1537-2073.2021-108. Epub 2022 Sep 8.
PMID: 36090238 Free PMC article.
34.
Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures. Lam KH, van Munster CEP, D’Souza M, Steinheimer S, Kamm CP, Burggraaff J, Johnson M, Zaykov Y, Dorn J, Dahlke F, Kappos L, Killestein J, Uitdehaag B.
Int J MS Care. 2022 Sep-Oct;24(5):230-234. doi: 10.7224/1537-2073.2021-044. Epub 2022 Jun 20.
PMID: 36090237 Free PMC article.
35.
Readmission Rates in Patients With Multiple Sclerosis: A Nationwide Cohort Study. Padarti A, Amritphale A, Kilgo W.
Int J MS Care. 2022 Sep-Oct;24(5):218-223. doi: 10.7224/1537-2073.2021-089. Epub 2022 May 3.
PMID: 36090236 Free PMC article.
36.
A case of childhood unilateral relapsing primary angiitis of the central nervous system. Onomura H, Furukawa S, Nishida S, Kitagawa S, Yoshida M, Ito Y.
Neuropathology. 2022 Sep 11. doi: 10.1111/neup.12866. Online ahead of print.
PMID: 36089838
1.
Synovial fluid and radiographic evaluation of joints from dogs with visceral leishmaniasis. Silva ARS, Gomes AAD, Aquino MCC, Almeida BFM, Lima VMF, Ciarlini PC, Pinoti LDR, Marcondes M, Vieira RFC.
Parasit Vectors. 2022 Sep 8;15(1):320. doi: 10.1186/s13071-022-05444-y.
PMID: 36076242
2.
Towards a global view of multiple sclerosis genetics. Jacobs BM, Peter M, Giovannoni G, Noyce AJ, Morris HR, Dobson R.
Nat Rev Neurol. 2022 Sep 8. doi: 10.1038/s41582-022-00704-y. Online ahead of print.
PMID: 36075979 Review.
3.
Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition. Lu S, Hu J, Arogundade OA, Goginashvili A, Vazquez-Sanchez S, Diedrich JK, Gu J, Blum J, Oung S, Ye Q, Yu H, Ravits J, Liu C, Yates JR 3rd, Cleveland DW.
Nat Cell Biol. 2022 Sep 8. doi: 10.1038/s41556-022-00988-8. Online ahead of print.
PMID: 36075972
4.
Perspective taking deficits and their relationship with theory of mind abilities in patients with relapsing-remitting multiple sclerosis (RRMS). Bruno D, Galiani A, Golfeder M, Pagani Cassará F, Duncan J, Sinay V, Roca M.
Appl Neuropsychol Adult. 2022 Sep 8:1-11. doi: 10.1080/23279095.2022.2114832. Online ahead of print.
PMID: 36075215
5.
Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Nabizadeh F, Masrouri S, Sharifkazemi H, Azami M, Nikfarjam M, Moghadasi AN.
J Clin Neurosci. 2022 Sep 5;105:37-44. doi: 10.1016/j.jocn.2022.08.020. Online ahead of print.
PMID: 36075186 Review.
6.
Discovery of new macrophage M2 polarization modulators as multiple sclerosis treatment agents that enable the inflammation microenvironment remodeling. Che J, Li D, Hong W, Wang L, Guo Y, Wu M, Lu J, Tong L, Weng Q, Wang J, Dong X.
Eur J Med Chem. 2022 Sep 2;243:114732. doi: 10.1016/j.ejmech.2022.114732. Online ahead of print.
PMID: 36075147
7.
Preclinical safety evaluation and tracing of human mesenchymal stromal cell spheroids following intravenous injection into cynomolgus monkeys. Yeung CK, Yan Y, Yan L, Duan Y, Li E, Huang B, Lu K, Li K, Zhou M, Zhang L, Wu Y, Luo KQ, Ji W, Xu RH, Si W.
Biomaterials. 2022 Aug 28;289:121759. doi: 10.1016/j.biomaterials.2022.121759. Online ahead of print.
PMID: 36075143
8.
Combined effect of gender differences and fatiguing task on postural balance, functional mobility and fall risk in adults with multiple sclerosis: A preliminary study. Jallouli S, Ben Dhia I, Sakka S, Mhiri C, Yahia A, Elleuch MH, Hammouda O, Ghroubi S.
Neurol Res. 2022 Sep 8:1-12. doi: 10.1080/01616412.2022.2112370. Online ahead of print.
PMID: 36074940
9.
Accelerating Digitalization in Healthcare with the InSilicoTrials Cloud-Based Platform: Four Use Cases. Nicolò C, Sips F, Vaghi C, Baretta A, Carbone V, Emili L, Bursi R.
Ann Biomed Eng. 2022 Sep 8. doi: 10.1007/s10439-022-03052-6. Online ahead of print.
PMID: 36074307
10.
Iron deposition in multiple sclerosis: overall load or distribution alteration? Hamdy E, Galeel AA, Ramadan I, Gaber D, Mustafa H, Mekky J.
Eur Radiol Exp. 2022 Sep 8;6(1):49. doi: 10.1186/s41747-022-00279-9.
PMID: 36074209
11.
Automated detection of hyperreflective foci in the outer nuclear layer of the retina. Schmidt MF, Christensen JL, Dahl VA, Toosy A, Petzold A, Hanson JVM, Schippling S, Frederiksen JL, Larsen M.
Acta Ophthalmol. 2022 Sep 8. doi: 10.1111/aos.15237. Online ahead of print.
PMID: 36073938
12.
Community Awareness Toward Multiple Sclerosis in the Western Region of Saudi Arabia: A Cross-Sectional Study. Dahlawi M, Ghazzawi MA, Alharthi SM, Yanksar EA, Almurakshi MM, Khatteb FR, Azher R, Jawi M, Algahtani R.
Cureus. 2022 Sep 2;14(9):e28689. doi: 10.7759/cureus.28689. eCollection 2022 Sep.
PMID: 36072780 Free PMC article.
13.
Sensitivity and Specificity of Central Vein Sign as a Diagnostic Biomarker in Egyptian Patients with Multiple Sclerosis. Abdel Ghany H, Karam-Allah A, Edward R, Abdel Naseer M, Hegazy MI.
Neuropsychiatr Dis Treat. 2022 Sep 1;18:1985-1992. doi: 10.2147/NDT.S377877. eCollection 2022.
PMID: 36072679 Free PMC article.
14.
CAQK, a peptide associating with extracellular matrix components targets sites of demyelinating injuries. Abi-Ghanem C, Jonnalagadda D, Chun J, Kihara Y, Ranscht B.
Front Cell Neurosci. 2022 Aug 22;16:908401. doi: 10.3389/fncel.2022.908401. eCollection 2022.
PMID: 36072569 Free PMC article.
15.
Systemic Sclerosis, Malnutrition, and Small Bowel Obstruction: Why Clinicians Should Consider Early Total Parenteral Nutrition in Systemic Sclerosis With Severe Gastrointestinal Involvement. Massat B, McCarthy J.
Cureus. 2022 Aug 3;14(8):e27638. doi: 10.7759/cureus.27638. eCollection 2022 Aug.
PMID: 36072159 Free PMC article.
16.
Editorial: Disease modifying therapies in multiple sclerosis. Bonavita S, Ghajarzadeh M, Lavorgna L.
Front Neurol. 2022 Aug 22;13:927321. doi: 10.3389/fneur.2022.927321. eCollection 2022.
PMID: 36071892 Free PMC article. No abstract available.
17.
Reduced brain oxygen metabolism in patients with multiple sclerosis: Evidence from dual-calibrated functional MRI. Chandler HL, Stickland RC, Patitucci E, Germuska M, Chiarelli AM, Foster C, Bhome-Dhaliwal S, Lancaster TM, Saxena N, Khot S, Tomassini V, Wise RG.
J Cereb Blood Flow Metab. 2022 Sep 7:271678X221121849. doi: 10.1177/0271678X221121849. Online ahead of print.
PMID: 36071645
18.
Longitudinal change in ATN biomarkers in cognitively normal individuals. Ebenau JL, Visser D, Kroeze LA, van Leeuwenstijn MSSA, van Harten AC, Windhorst AD, Golla SVS, Boellaard R, Scheltens P, Barkhof F, van Berckel BNM, van der Flier WM.
Alzheimers Res Ther. 2022 Sep 3;14(1):124. doi: 10.1186/s13195-022-01069-6.
PMID: 36057616 Free PMC article.
19.
CD8+ T cells in neurodegeneration: friend or foe? Hu D, Xia W, Weiner HL.
Mol Neurodegener. 2022 Sep 2;17(1):59. doi: 10.1186/s13024-022-00563-7.
PMID: 36056406 Free PMC article. No abstract available.
1.
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses. Pfeuffer S, Rolfes L, Wirth T, Steffen F, Pawlitzki M, Schulte-Mecklenbeck A, Gross CC, Brand M, Bittner S, Ruck T, Klotz L, Wiendl H, Meuth SG.
J Neuroinflammation. 2022 Sep 7;19(1):220. doi: 10.1186/s12974-022-02583-y.
PMID: 36071461
2.
Regaining Autonomy in a Holding Environment: Patients’ Perspectives on the Existential Communication with Physicians When Suffering from a Severe, Chronic Illness: A Qualitative Nordic Study. Andersen AH, Illes Z, Roessler KK.
J Relig Health. 2022 Sep 7. doi: 10.1007/s10943-022-01658-7. Online ahead of print.
PMID: 36071298
3.
Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic. Heidler F, Baldt J, Frahm N, Langhorst SE, Mashhadiakbar P, Streckenbach B, Burian K, Zettl UK, Richter J.
Sci Rep. 2022 Sep 7;12(1):15147. doi: 10.1038/s41598-022-18912-3.
PMID: 36071083
4.
Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatment. Peresson M, Cottone S, Brescia Morra V, Salemi G, Gallo A, Valentino P, Prosperini L.
Neurodegener Dis Manag. 2022 Sep 7. doi: 10.2217/nmt-2021-0016. Online ahead of print.
PMID: 36069572
5.
Compensatory Saccades Differ for Those with Vestibular Hypofunction and Multiple Sclerosis Pointing to Unique Roles for Peripheral and Central Vestibular Inputs. Wagner AR, Grove CR, Loyd BJ, Dibble LE, Schubert MC.
J Neurophysiol. 2022 Sep 7. doi: 10.1152/jn.00220.2022. Online ahead of print.
PMID: 36069428
6.
Complementary and alternative medicine in multiple sclerosis: a questionnaire-based study. Podlecka-Piętowska A, Sugalska M, Janiszewska K, Wall-Szczech A, Cyganek A, Szejko N, Zakrzewska-Pniewska B.
Neurol Neurochir Pol. 2022 Sep 7. doi: 10.5603/PJNNS.a2022.0059. Online ahead of print.
PMID: 36069151
7.
[Application and research progress of optical coherence tomography angiography in central nervous system diseases]. Shao YH, Jiang LB.
Zhonghua Yan Ke Za Zhi. 2022 Sep 11;58(9):731-735. doi: 10.3760/cma.j.cn112142-20210907-00415.
PMID: 36069100 Chinese.
8.
Highly efficient radiosynthesis and biological evaluation of [18F]safinamide, a radiolabelled anti-parkinsonian drug for PET imaging. Xu Y, Cen P, Ma L, Tian M, Zhang X, Zhang Q, Yu K, Zhang H, Gu W, He Q.
ChemMedChem. 2022 Sep 6. doi: 10.1002/cmdc.202200472. Online ahead of print.
PMID: 36068922
9.
Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know? Paybast S, Emami A, Baghalha F, Naser Moghadasi A.
Mult Scler Relat Disord. 2022 Sep;65:103960. doi: 10.1016/j.msard.2022.103960. Epub 2022 Jun 10.
PMID: 35763914 Free PMC article. Review.
Napsat komentář
Pro přidávání komentářů se musíte nejdříve přihlásit.